Advertisement

Rheumatology International

, Volume 39, Issue 1, pp 83–87 | Cite as

Is age associated with disease severity and compliance to treatment in children with familial Mediterranean fever?

  • Hafize Emine Sönmez
  • Pelin Esmeray
  • Ezgi Deniz Batu
  • Zehra Serap Arıcı
  • Selcan Demir
  • Erdal Sağ
  • Seza Özen
  • Yelda BilginerEmail author
Observational Research
  • 96 Downloads

Abstract

Familial Mediterranean Fever (FMF) is the most common monogenic autoinflammatory disease in the world. The disease characteristics may vary in different age groups. In this study, we aimed to compare disease characteristics and treatment compliance according to the age of pediatric FMF patients. This is a single-center, cross-sectional study. Between August and October 2016, patients who were diagnosed with FMF, participated to the study. 378 pediatric FMF patients were enrolled in the study. Among those, age at symptom onset was ≤ 5 years in 69%, 6–11 years in 26% and ≥ 12 years in 5%. Patients older than 12 years old at symptom onset, had significantly less frequent fever attacks than the patients from other age groups. Patients younger than 5 years old at symptom onset had significantly higher international severity scoring system for FMF (ISSF) than other patients. And M694V homozygosity was significantly more frequent in patients with younger age at symptom onset. Patients younger than 5 years old were using their drugs more regularly than the other age groups (p = 0.002). Drug compliance was 90.5% in patients ≤ 5 years, 64.4% in patients 6–11 years, 58.3% in patients ≥ 12 years. The disease characteristics of FMF may differ between patients with different age at symptom onset. Younger age at disease onset seems to be related with more severe course; thus these patients should be followed-up more closely. In addition, treatment compliance which is critical for prevention of amyloidosis in FMF should be questioned especially in adolescent patients.

Keywords

Familial Mediterranean fever Adherence to colchicine Severity 

Notes

Funding

No funding support was received for this study.

Compliance with ethical standards

Conflict of interest

The authors report no conflicts of interest.

Ethical approval

The study was approved by the ethics committee of Hacettepe University (GO-16/187−48; approval date, 10th May 2016).

References

  1. 1.
    The International FMF Consortium (1997) Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 90:797–807CrossRefGoogle Scholar
  2. 2.
    French FMF, Consortium (1997) A candidate gene for familial Mediterranean fever. Nat Genet 17:25–31CrossRefGoogle Scholar
  3. 3.
    Majeed HA, Rawashdeh M, el-Shanti H, Qubain H, Khuri-Bulos N, Shahin HM (1999) Familial Mediterranean fever in children: the expanded clinical profile. QJM 92:309–318CrossRefGoogle Scholar
  4. 4.
    Yalcinkaya F, Ozcakar ZB, Tanyildiz M, Elhan AH (2011) Familial Mediterranean fever in small children in Turkey. Clin Exp Rheumatol 29:87–90Google Scholar
  5. 5.
    Padeh S, Gerstein M, Berkun Y (2012) Colchicine is a safe drug in children with familial Mediterranean fever. J Pediatr 161:1142–1146CrossRefGoogle Scholar
  6. 6.
    Corsia A, Georgin-Lavialle S, Hentgen V et al (2017) A survey of resistance to colchicine treatment for French patients with familial Mediterranean fever. Orphanet J Rare Dis 12:54CrossRefGoogle Scholar
  7. 7.
    Yesilkaya S, Acikel C, Fidanci BE et al (2015) Development of a medication adherence scale for familial Mediterranean fever (MASIF) in a cohort of Turkish children. Clin Exp Rheumatol 33:156–162Google Scholar
  8. 8.
    Yalcinkaya F, Ozen S, Ozçakar ZB et al (2009) A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology 48:395–398CrossRefGoogle Scholar
  9. 9.
    Demirkaya E, Acikel C, Hashkes P et al; FMF Arthritis Vasculitis and Orphan disease Research in pediatric rheumatology (FAVOR) (2016) Development and initial validation of international severity scoring system for familial Mediterranean fever (ISSF). Ann Rheum Dis 75:1051–1056CrossRefGoogle Scholar
  10. 10.
    Piram M, Koné-Paut I, Lachmann HJ et al (2014) Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes. Ann Rheum Dis 73:2168–2173CrossRefGoogle Scholar
  11. 11.
    Ozen S, Demirkaya E, Erer B et al (2016) EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis 75:644–651CrossRefGoogle Scholar
  12. 12.
    Padeh S, Livneh A, Pras E, Shinar Y, Lidar M, Feld O, Berkun Y (2010) Familial Mediterranean fever in children presenting with attacks of fever alone. J Rheumatol 37:865–869CrossRefGoogle Scholar
  13. 13.
    Padeh S, Livneh A, Pras E, Shinar Y, Lidar M, Feld O, Berkun Y (2010) Familial Mediterranean fever in the first two years of life: a unique phenotype of disease in evolution. J Pediatr 156:985–989CrossRefGoogle Scholar
  14. 14.
    Pelajo CF, Sgarlat CM, Lopez-Benitez JM et al (2012) Adherence to methotrexate in juvenile idiopathic arthritis. Rheumatol Int 32:497–500CrossRefGoogle Scholar
  15. 15.
    Feldman DE, de Civita M, Dobkin PL, Malleson P, Meshefedjian G, Duffy CM (2007) Perceived adherence to prescribed treatment in juvenile idiopathic arthritis over a one-year period. Arthritis Rheum 57:226–233CrossRefGoogle Scholar
  16. 16.
    Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487–497CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Hafize Emine Sönmez
    • 1
  • Pelin Esmeray
    • 2
  • Ezgi Deniz Batu
    • 3
  • Zehra Serap Arıcı
    • 4
  • Selcan Demir
    • 1
  • Erdal Sağ
    • 1
  • Seza Özen
    • 1
  • Yelda Bilginer
    • 1
    Email author
  1. 1.Department of Pediatrics, Division of RheumatologyHacettepe University Faculty of MedicineAnkaraTurkey
  2. 2.Department of PediatricsErzurum Training and Research HospitalErzurumTurkey
  3. 3.Department of Pediatrics, Division of Rheumatology, Ankara Training and Research HospitalUniversity of Health SciencesAnkaraTurkey
  4. 4.Department of Pediatric RheumatologyŞanlıurfa Training and Research HospitalŞanlıurfaTurkey

Personalised recommendations